Thyrocare Technologies 将来の成長

Future 基準チェック /56

Thyrocare Technologies利益と収益がそれぞれ年間26.9%と16.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に25.3% 27.2%なると予測されています。

主要情報

26.9%

収益成長率

27.2%

EPS成長率

Healthcare 収益成長	27.4%
収益成長率	16.3%
将来の株主資本利益率	25.3%
アナリストカバレッジ	Low
最終更新日	24 Oct 2024

今後の成長に関する最新情報

Recent updates

業績と収益の成長予測

BSE:539871 - アナリストの将来予測と過去の財務データ ( )INR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2027	9,319	1,647	2,087	2,074	2
3/31/2026	8,062	1,319	1,737	1,733	2
3/31/2025	6,828	998	1,595	1,559	2
9/30/2024	6,233	840	1,648	1,873	N/A
6/30/2024	5,939	776	N/A	N/A	N/A
3/31/2024	5,719	708	1,061	1,676	N/A
12/31/2023	5,535	655	N/A	N/A	N/A
9/30/2023	5,468	648	647	1,418	N/A
6/30/2023	5,338	599	N/A	N/A	N/A
3/31/2023	5,267	645	857	1,293	N/A
12/31/2022	5,214	731	N/A	N/A	N/A
9/30/2022	5,108	800	749	1,001	N/A
6/30/2022	5,520	1,423	N/A	N/A	N/A
3/31/2022	5,889	1,761	756	1,134	N/A
12/31/2021	6,051	1,924	N/A	N/A	N/A
9/30/2021	6,260	2,032	1,249	1,642	N/A
6/30/2021	6,030	1,685	N/A	N/A	N/A
3/31/2021	4,946	1,132	880	1,147	N/A
12/31/2020	4,503	741	N/A	N/A	N/A
9/30/2020	4,178	692	789	1,004	N/A
6/30/2020	3,797	612	N/A	N/A	N/A
3/31/2020	4,343	884	1,580	1,679	N/A
12/31/2019	4,384	1,063	N/A	N/A	N/A
9/30/2019	4,289	990	1,305	1,436	N/A
6/30/2019	4,165	892	N/A	N/A	N/A
3/31/2019	4,039	851	601	1,003	N/A
12/31/2018	3,946	939	N/A	N/A	N/A
9/30/2018	3,822	953	N/A	N/A	N/A
6/30/2018	3,663	947	N/A	N/A	N/A
3/31/2018	3,569	933	N/A	1,070	N/A
12/31/2017	3,493	1,117	N/A	N/A	N/A
9/30/2017	3,359	994	N/A	N/A	N/A
6/30/2017	3,258	759	N/A	N/A	N/A
3/31/2017	3,045	428	N/A	896	N/A
12/31/2016	2,843	659	N/A	N/A	N/A
9/30/2016	2,699	601	N/A	N/A	N/A
6/30/2016	2,535	564	N/A	N/A	N/A
3/31/2016	2,411	518	N/A	678	N/A
3/31/2015	1,835	452	N/A	345	N/A
3/31/2014	1,502	462	N/A	462	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 539871の予測収益成長率 (年間26.9% ) は貯蓄率 ( 6.7% ) を上回っています。

収益対市場: 539871の収益 ( 26.9% ) はIndian市場 ( 18.1% ) よりも速いペースで成長すると予測されています。

高成長収益: 539871の収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: 539871の収益 ( 16.3% ) Indian市場 ( 10.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 539871の収益 ( 16.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 539871の自己資本利益率は、3年後には高くなると予測されています ( 25.3 %)

Thyrocare Technologies 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 9.1% to ₹903

Price target increased by 8.5% to ₹828

Consensus EPS estimates increase by 11%

Price target increased by 8.1% to ₹800

Price target increased by 7.3% to ₹695

Price target decreased by 18% to ₹643

Recent updates

MD, CEO & Chairman recently bought ₹1.1m worth of stock

Price target increased by 9.1% to ₹903

Second quarter 2025 earnings released: EPS: ₹4.99 (vs ₹3.84 in 2Q 2024)

High number of new directors

Thyrocare Technologies Limited to Report Q2, 2025 Results on Oct 23, 2024

Now 23% overvalued after recent price rise

Price target increased by 8.5% to ₹828

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Diagnostics and and pathological services business of Virnta Labs Limited from Vimta Labs Limited (BSE:524394) for INR 70 million.

Thyrocare Technologies Limited Announces Cessation of Mr. Neetin Shivajirao Desai as Independent Director as Well as Member of the Respective Committee(s) of the Board

Now 20% overvalued after recent price rise

Thyrocare Technologies Limited Approves Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited Announces Cessation of Gopalkrishna Shivaram Hegde as Independent Director and as Member / Chairman of the Respective Committee

Now 20% overvalued after recent price rise

Upcoming dividend of ₹18.00 per share

Thyrocare Technologies Limited, Annual General Meeting, Aug 23, 2024

Consensus EPS estimates increase by 11%

Thyrocare Technologies Limited (BSE:539871) acquired Diagnostic and pathological services business of Polo Labs Private Limited for INR 42.6 million.

Price target increased by 8.1% to ₹800

Now 23% overvalued after recent price rise

First quarter 2025 earnings released: EPS: ₹4.52 (vs ₹3.26 in 1Q 2024)

Thyrocare Technologies Limited to Report Q1, 2025 Results on Jul 23, 2024

Now 23% overvalued after recent price rise

Thyrocare Technologies Limited Proposes Final Dividend for the Financial Year 2023-24

Thyrocare Technologies Limited to Report Q4, 2024 Results on May 14, 2024

Thyrocare Technologies Limited (BSE:539871) completed the acquisition of Think Health Diagnostic Private Limited.

High number of new directors

Third quarter 2024 earnings released: EPS: ₹2.78 (vs ₹1.89 in 3Q 2023)

Thyrocare Technologies Limited to Report Q3, 2024 Results on Feb 01, 2024

Price target increased by 7.3% to ₹695

Second quarter 2024 earnings released: EPS: ₹3.84 (vs ₹3.80 in 2Q 2023)

Thyrocare Technologies Limited to Report Q2, 2024 Results on Oct 31, 2023

MD, CEO & Chairman recently bought ₹4.3m worth of stock

Thyrocare Technologies Limited Appoints Alok Kumar Jagnani as Chief Financial Officer

Price target decreased by 18% to ₹643

High number of new directors

Thyrocare Technologies Limited to Report Q1, 2024 Results on Aug 01, 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited Accepts Resignation of Sachin Salvi as Chief Financial Officer

Consensus EPS estimates fall by 27%

Full year 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2023 Results on May 23, 2023

Thyrocare Technologies Limited Announces Resignation of Vishwas Kulkarni as an Independent Director

Upcoming dividend of ₹18.00 per share at 3.1% yield

MD, CEO & Director recently bought ₹10m worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q3, 2023 Results on Feb 03, 2023

Consensus EPS estimates fall by 19%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited (BSE:539871) agreed to acquire 51% stake in Pulse Hitech Health Services (Ghatkopar) LLP for INR 25.5 million.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q2, 2023 Results on Nov 11, 2022

MD, CEO & Director recently bought ₹16m worth of stock

Consensus EPS estimates fall by 12%

Thyrocare Technologies Limited Announces Payment of Interim Dividend for the Financial Year 2021-2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited, Annual General Meeting, Aug 03, 2022

Price target decreased to ₹1,073

Consensus forecasts updated

Thyrocare Technologies Limited Joins Rahul Guha as Managing Director

Thyrocare Technologies Limited Declares Interim Dividend for the Financial Year 2021-22

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thyrocare Technologies Limited to Report Q4, 2022 Results on Apr 29, 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Thyrocare Technologies Limited Announces Appointment of Rahul Guha as Managing Director

Thyrocare Technologies Limited Appoints Sachin Salvi as Chief Financial Officer

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Consensus forecasts updated

First quarter 2022 earnings released: EPS ₹10.51 (vs ₹0.04 in 1Q 2021)

Price target increased to ₹1,233